ANI PHARMACEUTICALS, INC Business Acquisition, Pro Forma Revenue
ANI PHARMACEUTICALS, INC (ANIP) reported Business Acquisition, Pro Forma Revenue of $272.89 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Income Statement › Other Income
us-gaap:BusinessAcquisitionsProFormaRevenue · last filed 2024-02-29
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for the quarter ending 2018-12-31 was $57.12M, a 12.28% increase year-over-year.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for the quarter ending 2018-09-30 was $51.38M, a 0.57% decline year-over-year.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for the quarter ending 2018-06-30 was $50.21M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for the quarter ending 2018-03-31 was $49.56M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for fiscal 2021 was $272.89M, a 4.57% increase from fiscal 2020.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for fiscal 2020 was $260.95M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for fiscal 2018 was $208.21M, a 10.31% increase from fiscal 2017.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma revenue for fiscal 2017 was $188.76M.
| Period end | Business Acquisition, Pro Forma Revenue 3 month | Business Acquisition, Pro Forma Revenue 3 month as first filed | Business Acquisition, Pro Forma Revenue 6 month | Business Acquisition, Pro Forma Revenue 6 month as first filed | Business Acquisition, Pro Forma Revenue 9 month | Business Acquisition, Pro Forma Revenue 9 month as first filed | Business Acquisition, Pro Forma Revenue 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $272.89M 10-K · filed 2024-02-29 | ||||||
| 2020-12-31 | $260.95M 10-K · filed 2023-03-09 | ||||||
| 2018-12-31 | $57.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $108.51M derived: sum of 2 quarters · filed 2021-03-11 | $158.71M derived: sum of 3 quarters · filed 2021-03-11 | $208.21M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $51.38M 10-Q · filed 2019-11-06 | $101.59M derived: sum of 2 quarters · filed 2019-11-06 | $151.09M 10-Q · filed 2019-11-06 | $202.02M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-06-30 | $50.21M 10-Q · filed 2019-08-07 | $99.76M 10-Q · filed 2019-08-07 | $150.64M derived: sum of 3 quarters · filed 2021-03-11 | $202.31M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-03-31 | $49.56M 10-Q · filed 2019-05-09 | $100.43M derived: sum of 2 quarters · filed 2021-03-11 | $152.11M derived: sum of 3 quarters · filed 2021-03-11 | ||||
| 2017-12-31 | $50.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $102.55M derived: sum of 2 quarters · filed 2021-03-11 | $188.76M 10-K · filed 2021-03-11 | ||||
| 2017-09-30 | $51.68M 10-Q · filed 2018-11-06 | $137.88M 10-Q · filed 2018-11-06 | |||||
| 2013-12-31 | $10.53M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $18.37M derived: sum of 2 quarters · filed 2016-02-23 | $24.52M derived: sum of 3 quarters · filed 2016-02-23 | $30.23M 10-K · filed 2016-02-23 | |||
| 2013-09-30 | $7.84M 10-Q · filed 2014-11-10 | $7.84M 10-Q · filed 2013-11-07 | $13.99M derived: sum of 2 quarters · filed 2014-11-10 | $19.70M 10-Q · filed 2014-11-10 | $19.69M 10-Q · filed 2013-11-07 | $26.98M derived: sum of 4 quarters · filed 2014-11-10 | |
| 2013-06-30 | $6.15M 10-Q · filed 2014-08-07 | $6.15M 10-Q · filed 2013-08-09 | $11.86M 10-Q · filed 2014-08-07 | $11.86M 10-Q · filed 2013-08-09 | $19.15M derived: sum of 3 quarters · filed 2014-08-07 | $24.29M derived: sum of 4 quarters · filed 2014-08-07 | |
| 2013-03-31 | $5.71M 10-Q · filed 2014-05-12 | $13.00M derived: sum of 2 quarters · filed 2014-05-12 | $18.14M derived: sum of 3 quarters · filed 2014-05-12 | $23.44M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | $7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $12.43M derived: sum of 2 quarters · filed 2014-02-28 | $17.73M derived: sum of 3 quarters · filed 2014-02-28 | $22.67M 10-K · filed 2014-02-28 | |||
| 2012-09-30 | $5.15M 10-Q · filed 2013-11-07 | $10.44M derived: sum of 2 quarters · filed 2013-11-07 | $15.38M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | $5.30M 10-Q · filed 2013-08-09 | $10.24M 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |